ETHNOPHARMACOLOGICAL RELEVANCE
The regulation policies of substances used in Chinese Herbal Medicine (CHM), have a direct influence on the ability of health providers to practice in the clinic.
AIM OF THE STUDY
We set out to assess the truth behind the assumption that practice of CHM in the west is constrained by the regulations imposed by authorities in western countries.
MATERIALS AND METHODS
For the first part of our study we surveyed and compiled lists of banned and restricted Chinese Materia Medica (CMM) from six countries: USA, UK, Germany, Israel, Canada and Australia. Afterwards, we estimated the relevant importance of the 300 CMM most-commonly-prescribed to the practice of CHM according to prescriptions from 2,000,000 randomly selected patients, from the Taiwanese National Health Insurance Research Database (NHIRD). We then compared both lists and determined the clinical importance of the banned and restricted CMM.
RESULTS
Except for regulations from Canada, most of the information of banned CMM proved to be difficult to organize. The USA was found to have the least amount of banned herbs, with 9 substances. Canada had the highest amount, with 98. In Germany, Australia, the UK, and Israel 10, 29, 36, 68 banned CMM were found, respectively. Apart from aristolochic acid containing substances, ma huang (, Ephedra sinica) was the only CMM banned in all countries. Most of the banned CMM were not found to be among the most-commonly-prescribed according to the NHIRD.
CONCLUSION
Authorities should make this information more accessible. No clear relation exists between CHM regulations and any 'Western' common denominator, and the amount of banned CMM varied greatly among the surveyed countries. However, even among countries with a larger amount of banned CMM, the majority of these were in the bottom two-thirds in respect to the frequency of their use. Thus, regulations in some western countries surely influence the practice of CHM, however, the variability of CMM have been influenced by regulations only to a limited extent.
[1]
Vivian Chi-Woon Taam Wong,et al.
Future development of global regulations of Chinese herbal products.
,
2012,
Journal of ethnopharmacology.
[2]
Jianxin Chen,et al.
Papers published from 1995 to 2012 by six Traditional Chinese Medicine universities in China: a bibliometric analysis based on science citation index.
,
2013,
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan.
[3]
J. W. Salmon,et al.
Herbal Medicine Regulation in China, Germany, and the United States
,
2010
.
[4]
K. Kaphle,et al.
Herbal Medicine Research in Taiwan
,
2006,
Evidence-based complementary and alternative medicine : eCAM.
[5]
陳方周,et al.
Use frequency of traditional Chinese medicine in Taiwan
,
2007
.
[6]
K. Kawakita,et al.
Public Status and Prevalence of Acupuncture in Japan
,
2008,
Evidence-based complementary and alternative medicine : eCAM.
[7]
F. Debellé,et al.
Aristolochic acid nephropathy: a worldwide problem.
,
2008,
Kidney international.
[8]
S. Conroy,et al.
Drug trials in children: problems and the way forward.
,
2000,
British journal of clinical pharmacology.